中藥複方清冠止咳一號改善新冠肺炎急性後期咳嗽之病例報告

A Case Report of Traditional Chinese Medicine Compound QING-GUAN-ZHI-KE-YI-HAO in Improving Cough in the Late Acute Phase of COVID-19

本病例報告了一名45歲男性台灣患者，確診新冠肺炎後持續咳嗽且呼吸頻率增加，胸口壓迫感而常需要深呼吸，以及鼻塞和流鼻涕等症狀。病患接受了新冠肺炎後遺症專方「清冠止咳一號」治療三週。清冠止咳一號是一種中藥方劑，含有麻黃、杏仁、紫蘇葉、麥門冬、桑葉、枇杷葉、石膏、黨參、紅棗、甘草和貝母等成分。治療三週。治療後，患者的症狀評估量表結果明顯改善，呼吸困難和體力活動時感受顯著減輕。慢性阻塞性肺病症狀評估量表(CAT)治療前的總評分為20分，治療後第一週降至19分，第二週降至12分，第三週降至5分。這顯示治療對咳嗽頻率、痰量、胸悶、喘促、居家活動、睡眠、咽喉乾燥等方面的改善效果已初見成效，且持續改善。綜合以上結果，清冠止咳一號治療對這名新冠肺炎後期患者具有積極臨床意義，改善了呼吸症狀並有助於生活品質和功能恢復。然而，需進一步研究和臨床驗證其療效。

This case report presents a 45-year-old Taiwanese male patient who was diagnosed with COVID-19 and experienced persistent cough, increased respiratory rate, chest oppression, and the need for deep breaths. The patient received a three-week treatment with the traditional Chinese medicine formula ''QING-GUAN-ZHI-KE-YI-HAO,'' specifically designed for post-COVID-19 symptoms. QING-GUAN-ZHI-KE-YI-HAO is a herbal prescription containing ingredients such as Ephedra, Apricot kernel, Perilla leaf, Ophiopogon, Mulberry leaf, Loquat leaf, Gypsum, Codonopsis, Red date, Licorice, and Fritillaria. After the treatment, the patient's symptom assessment scores significantly improved, with noticeable reductions in breathlessness and exertion during physical activity. The Chronic Obstructive Pulmonary Disease Assessment Test (CAT) score decreased from20 before treatment to 19 in the first week, 12 in the second week, and 5 in the third week. This indicates significant improvement in cough frequency, sputum amount, chest tightness, breathlessness, home activities, sleep, throat dryness, and continued improvement over the course of treatment. In conclusion, the use of QING-GUAN-ZHI-KE-YI-HAO in the treatment of this post-COVID-19 patient showed positive clinical significance, improving respiratory symptoms and contributing to the patient's quality of life and functional recovery. However, further research and clinical validation are warranted to establish its efficacy.